J Med Virol. 2020 May 7. doi: 10.1002/jmv.25992. [Epub ahead of print]
ACE2 Activators for the Treatment of Covid 19 Patients.
Puertas RR1.
Author information
Abstract
The paper of Cheng H. et al., describes an interesting hypothesis regarding the organ protective effects of ACE2 activation against the malignant effects of SARS-CoV-2 infection in humans, and describes interesting previous results reporting ACE2 higher levels in children, young people and women that is coincident with a lower morbidity and health problems associated to COVID19. In the present comment the treatment of COVID19 patients with ACE2 activators, such as diminazene aceturate (DIZE), which are currently used as antiparasitic drugs, is proposed. This article is protected by copyright. All rights reserved.
This article is protected by copyright. All rights reserved.
KEYWORDS:
SARS-CoV-2 coronavirus disease 2019, COVID19; angiotensin II receptor blockers, ARBs; angiotensin-converting enzyme 2, ACE2; angiotensin-converting enzyme inhibitors, ACEI; diminazene aceturate, DIZE
PMID:32379346DOI:10.1002/jmv.25992